17 results about "Propranolol" patented technology

The present disclosure provides, among other things, methods, compositions, and uses for treating diseases or disorders characterized by elevated red blood cells using β2 adrenergic receptor antagonists such as β2-specific adrenergic receptor antagonists (e.g., ICI-118551, butaxamine, or pharmaceutically acceptable salts thereof) or β1 / β2-specific adrenergic receptor antagonists (e.g., propranolol or a pharmaceutically acceptable salt thereof). Also provided are methods, compositions, and uses for decreasing erythroid differentiation using the same. Provided methods of treatment comprise administering an effective amount of a β2-specific adrenergic receptor antagonist or a β1 / β2-specific adrenergic receptor antagonist to a patient in need thereof. Also provided are methods, compositions, and uses for ICI-118551 in treating splenomegaly, splenic erythroid hyperplasia, and / or splenic architecture effacement.

The invention provides a method for rapidly screening illegally added propranolol in a functional beverage, which adopts a liquid phase microextraction technology to separate and enrich a sample, adopts an ultraviolet visible spectrophotometer to detect illegally added propranolol, and adopts an external standard method to quantify, the established method has good linearity, the correlation coefficient of propranolol is greater than 0.999, and the result shows that the method can be used for rapidly screening the illegally added propranolol. The detection limit is 97.2 [mu] g / L, the recovery rate is 95.5%-108.1%, and the relative standard deviation (RSD) is 0.99%-5.59%. The method is good in accuracy, high in precision and sensitivity and suitable for rapidly, qualitatively and quantitatively screening the propranolol illegally added in the functional beverage.

Copper-boron-ferrite (Cu—B—Fe) composites may be prepared and immobilized on graphite electrodes in a silica-based sol-gel, e.g., from rice husks. Different bimetallic loading ratios can produce fast in-situ electrogeneration of reactive oxygen species, H2O2 and ·OH, e.g., via droplet flow-assisted heterogeneous electro-Fenton reactor system. Loading ratios of, e.g., 10 to 30 wt. % Fe3+ and 5 to 15% wt. Cu2+, can improve the catalytic activities towards pharmaceutical beta blockers (atenolol and propranolol) degradation in water. Degradation efficiencies of at least 99.9% for both propranolol and atenolol in hospital wastewater were demonstrated. Radicals of ·OH in degradation indicate a surface mechanism at inventive cathodes with correlated contributions of iron and copper. Copper and iron can be embedded in porous graphite electrode surface and catalyze the conversion of H2O2 to ·OH to enhance the degradation. Inventive cathodes can be stable catalytically after 20 or more cycles under neutral and acidic conditions.

The present invention discloses a capillary monolithic column modified with a deoxyribozyme nanoflower, a preparation method thereof, and an application thereof in separating chiral molecules, belonging to the field of pharmaceutical analysis. The present invention synthesizes a deoxyribozyme-based nanoflower chiral selector, the nucleotide sequence of the single-stranded DNA template of the deoxyribozyme being shown in SEQ ID NO.1, and the synthesized deoxyribozyme nanoflower having good pH and temperature stability. The prepared deoxyribozyme nanoflower is bonded to a graphene oxide-functionalized capillary silica monolithic column, and chiral molecules are separated under electrophoretic conditions, achieving baseline separation of 2'-deoxyadenosine, atenolol, propranolol, tyrosine, and nafopam enantiomers.

The invention discloses a pharmaceutical composition containing propranolol and a neutral endo-peptidase inhibitor, the pharmaceutical composition comprises propranolol and a neutral endo-peptidase inhibitor, and the propranolol and the neutral endo-peptidase inhibitor are combined and connected through a non-covalent bond. According to the invention, sacubitril and propranolol are combined into a dual-effect salt, so that the two active pharmaceutical ingredients are synchronously released, the drug effect is favorably improved, the synergistic effect is favorably generated in the treatment process, the side effect of propranolol is effectively reduced, and the clinical use values of sacubitril and propranolol are potentially improved; on the premise of ensuring the antihypertensive effect, the occurrence probability of side effects is effectively reduced, and the medication safety is improved.

The invention relates to a medicament or method for topically treating hemangioma, comprising, or administering, Propranolol and Fosinopril in a molar ratio of 2 to 0.9 - 1.3 respectively. The invention also relates to the use of Propranolol and Fosinopril in the manufacture of a medicament for topical administration to a human patient for treating hemangioma, where the Propranolol and Fosinopril are in a molar ratio of 2 to 0.9 - 1.3.

The invention belongs to the field of biological medicines and skin care products, provides an efficient transdermal absorption type beta receptor blocker and further provides a preparation method of the efficient transdermal absorption type beta receptor blocker, and the efficient transdermal absorption type beta receptor blocker is obtained by performing esterification reaction on amentoflavone and butyric anhydride. The invention also provides an application of the efficient transdermal absorption type beta receptor blocker. The efficient transdermal absorption type beta receptor blocker is used for preparing a transdermal absorption preparation of the beta blocker for preventing or treating skin problems caused by mental stress. The efficient transdermal absorption type beta receptor blocking agent has efficient beta receptor blocking and efficient transdermal absorption capabilities, and is obviously superior to the existing clinical beta receptor blocking agent propranolol; the transdermal absorption preparation containing the efficient transdermal absorption type beta receptor blocker can be used for preventing or treating skin problems caused by mental stress.

Copper-boron-ferrite (Cu—B—Fe) composites may be prepared and immobilized on graphite electrodes in a silica-based sol-gel, e.g., from rice husks. Different bimetallic loading ratios can produce fast in-situ electrogeneration of reactive oxygen species, H2O2 and ·OH, e.g., via droplet flow-assisted heterogeneous electro-Fenton reactor system. Loading ratios of, e.g., 10 to 30 wt. % Fe3+ and 5 to 15% wt. Cu2+, can improve the catalytic activities towards pharmaceutical beta blockers (atenolol and propranolol) degradation in water. Degradation efficiencies of at least 99.9% for both propranolol and atenolol in hospital wastewater were demonstrated. Radicals of ·OH in degradation indicate a surface mechanism at inventive cathodes with correlated contributions of iron and copper. Copper and iron can be embedded in porous graphite electrode surface and catalyze the conversion of H2O2 to ·OH to enhance the degradation. Inventive cathodes can be stable catalytically after 20 or more cycles under neutral and acidic conditions.

Copper-boron-ferrite (Cu—B—Fe) composites may be prepared and immobilized on graphite electrodes in a silica-based sol-gel, e.g., from rice husks. Different bimetallic loading ratios can produce fast in-situ electrogeneration of reactive oxygen species, H2O2 and ·OH, e.g., via droplet flow-assisted heterogeneous electro-Fenton reactor system. Loading ratios of, e.g., 10 to 30 wt. % Fe3+ and 5 to 15% wt. Cu2+, can improve the catalytic activities towards pharmaceutical beta blockers (atenolol and propranolol) degradation in water. Degradation efficiencies of at least 99.9% for both propranolol and atenolol in hospital wastewater were demonstrated. Radicals of ·OH in degradation indicate a surface mechanism at inventive cathodes with correlated contributions of iron and copper. Copper and iron can be embedded in porous graphite electrode surface and catalyze the conversion of H2O2 to ·OH to enhance the degradation. Inventive cathodes can be stable catalytically after 20 or more cycles under neutral and acidic conditions.

A medicament for treating a cutaneous scar, comprising a combination of Nintedanib and Propranolol.

The invention provides propranolol temperature-sensitive hydrogel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The propranolol temperature-sensitive hydrogel disclosed by the invention is prepared from chitosan-beta-sodium glycerophosphate hydrogel and nano microspheres loaded on the chitosan-beta-sodium glycerophosphate hydrogel, wherein the chitosan-beta-sodium glycerophosphate hydrogel is a chitosan-beta-sodium glycerophosphate hydrogel; the nano microspheres are chitosan microspheres which are used for encapsulating propranolol; the mass of the nano microspheres is 1%-20% of the mass of the chitosan-beta-sodium glycerophosphate hydrogel. The propranolol temperature-sensitive hydrogel provided by the invention is a dual slow-release temperature-sensitive hydrogel system, not only has remarkable controlled release performance, can release drugs more continuously and stably, but also has good drug loading property and stable rheological property.

The present invention discloses bone-targeted alendronate-propranolol and its preparation method and application. The bone-targeted alendronate-propranolol has good in vitro bone targeting and dissociates and releases the propranolol original drug in the bone microenvironment in vivo, which can inhibit osteoclasts and has a certain protective effect on bone tissue. At the same time, it can also inhibit the growth of tumors after breast cancer bone metastasis, and is expected to provide a new treatment method for breast cancer bone metastasis. The synthesis route and post-processing method of the present invention are safe and simple, the synthetic raw materials and solvents used are cheap and easy to obtain, and the intermediate compounds and target products have high yields. The present invention also proposes the application of bone-targeted alendronate-propranolol in the preparation of drugs for treating breast cancer bone metastasis.

The invention discloses a method for removing propranolol by activating calcium sulfite with a bimetallic MOFs material, which comprises the following steps: dissolving ferrous chloride tetrahydrate, cobalt nitrate hexahydrate and terephthalic acid in a mixed solution of N, N-dimethylformamide, methanol and ultrapure water, magnetically stirring, carrying out hydrothermal reaction after stirring, centrifugally recovering to obtain a precipitate, and drying to obtain the propranolol. Washing and drying the precipitate to obtain MOF-(Fe, Co); and adding the MOF-(Fe, Co) and calcium sulfite into a water sample containing propranolol. According to the method, the limitations of low conductivity, single unsaturated metal type, easy inactivation in the reaction process and the like of a monometal MOFs material are overcome, the problem of reactive active species quenching caused by high solubility of Na2SO3 in water is solved, and efficient removal of propranolol in water is realized through the synergistic effect of the bimetal MOFs material and calcium sulfite.

The invention provides application of propranolol or pharmaceutically acceptable salts thereof in preparation of drugs for inhibiting lung cancer meningeal metastasis. The invention discloses the application of blocking neuroendocrine differentiation in prevention and treatment of tumor meningeal metastasis for the first time, the neuroendocrine differentiation of lung cancer is blocked by propranolol, and the survival ability of lung cancer cells in a cerebrospinal fluid environment can be weakened, so that the lung cancer meningeal metastasis is inhibited, and the lung cancer is finally improved or treated. Neuroendocrine differentiation is found to be a key regulation factor of lung cancer meningeal metastasis, and potential development prospects are achieved by blocking lung cancer neuroendocrine differentiation through propranolol so as to inhibit lung cancer meningeal metastasis.

The invention belongs to the field of biological medicine, and particularly relates to application of propranolol in preparation of an oncolytic virus anti-tumor synergist and a medicinal composition. According to the application disclosed by the invention, the propranolol is used as an auxiliary medicine for tumors, can be used for remarkably enhancing the replication efficiency of the oncolytic virus in CMT-U27 cells when being combined with the oncolytic virus Newcastle disease virus NDV, and can be used for generating a synergistic inhibition effect on the tumors when being combined; the propranolol enhances the in-vivo and in-vitro oncolytic effect by inhibiting an oncolytic virus activated I type interferon mediated JAK-STAT signal channel, obviously inhibits the growth and proliferation of tumors, has a better tumor inhibition rate, and provides reference for developing a new effective treatment method for tumors.

This invention discloses the application of GLPG0187 in combination with propranolol in the preparation of drugs for the treatment or inhibition of hemangiomas. GLPG0187 is an integrin β1 inhibitor, and propranolol is a β-receptor blocker. This invention was validated through CCK8 assays, scratch assays, and tube formation assays. The results showed that, compared with propranolol monotherapy, GLPG0187 (4 nM) combined with propranolol (20-30 μM) could further inhibit the proliferation, migration, and tube formation ability of human hemangioma endothelial cells, demonstrating superior efficacy compared to propranolol monotherapy. This invention addresses the issue that approximately 2.1% of patients treated with propranolol monotherapy for infantile hemangiomas experience side effects such as sleep disturbances, bronchospasm, and hypoglycemia, providing a new combination therapy regimen and offering a new drug option for reducing the clinical dosage of propranolol and minimizing the risk of side effects. This invention identifies a new target for the treatment of hemangiomas, providing new possibilities for hemangioma treatment.

The present invention relates to a synthesis process of propranolol, belonging to the technical field of pharmaceutical synthesis. A synthesis process of propranolol is provided. The method includes reacting 1-naphthol with 1-bromo-3-hydroxyacetone in an organic solvent to form Compound 3, 1-hydroxy-3-(1-naphthyloxy)-2-propanone; reacting Compound 3 with isopropylamine in an organic solvent to form Compound 2, 1-isopropylamino-3-(1-naphthyloxy)-2-propanone; and subjecting Compound 2 to a reduction reaction under the action of a catalyst to form Compound 1, 1-isopropylamino-3-(1-naphthyloxy)-2-propanol. Overall, the present invention has the advantages of less generation of by-products and impurities, high product yield, high product purity, and simple post-treatment.